An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...
In my November 2024 column, I began discussing the building block approach for crashworthiness testing of composite structures. This approach features a multistep process for designing composite ...
The performance of the final product depends heavily on the degree of cure - making it critical to ensure that the reaction goes to completion for the highest quality and reliability. Achieving this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback